Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
BUSINESS
Novo Training Its Sights on Oral Diabetes Market with Rybelsus, Not Switches from GLP-1 Injectables
Novo Nordisk Pharma is looking to pit its recently launched oral GLP-1 agent Rybelsus (semaglutide) against oral rivals like DPP-4 and SGLT2 inhibitors, rather than injectables in the same class, by pitching its strong efficacy in reducing HbA1c. On February…
To read the full story
Related Article
- 1st Oral GLP Agent Hits Japan Shelves
February 8, 2021
- 4 Drug Makers Flag GLP-1 Use for “Weight Loss” after Diabetes Society Warning
August 24, 2020
- Novo Joins Hands with MSD in Oral Semaglutide Promotion
December 10, 2019
BUSINESS
- CSL/Alfresa Roll Out Home Delivery Service of Hemophilia Drugs
October 4, 2023
- Takeda to Pull Lung Cancer Med Exkivity in US after Trial Miss
October 4, 2023
- Drug Makers Discontinue Sales of Alesion Dry Syrup, Generic Versions
October 3, 2023
- Meiji Launches Japan PIII of mRNA COVID Shot for BA.4/5 Strain
October 3, 2023
- Chugai Embraces ChatGPT to Streamline Internal Tasks, Search Research Papers and More
October 3, 2023
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…